Ï㽶ÊÓƵ

Theodore G. Liou
No Rating Available
(Learn About Our Rating System)

Theodore G. Liou, MD

Languages spoken: English

Clinical Locations

Ï㽶ÊÓƵ of Utah Hospital

Pulmonary, Clinic 3
Salt Lake City
801-581-7806

  • Theodore Liou, MD, is Director of the Adult CF Center at the Ï㽶ÊÓƵ of Utah, Professor of Internal Medicine and Adjunct Associate Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah. He is triple boarded in Internal, Pulmonary and Critical Care Medicine. He has taken care of patients with a highly individualized personal touch and directed the award winning team for CF for more than seventeen years.

    Dr. Liou's research interests include cystic fibrosis, sepsis, ARDS, airway inflammation, pneumonia, airway ecology and antibiotic discovery. He has landmark articles in cystic fibrosis and lung transplantation in journals including JAMA and the New England Journal of Medicine as well as articles with high impact in Lancet, the American Journal of Epidemiology, the American Journal of Respiratory and Critical Care Medicine, CHEST, the Journal of Cystic Fibrosis and others. He has been invited to speak at The Gordon Conference on Enzymes, Co-enzymes and Metabolic pathways, Mayo Clinic, McGill, Case Western, U Penn, Capitol Ï㽶ÊÓƵ Beijing, Children's Hospital LA, USC, Merck, Genentech, the North American CF Conference, the International Conference of the American Thoracic Society, the American Society of Microbiology, the International Society for Heart Lung Transplantation, the Italian CF Research Foundation and the annual European CF society Meetings.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Critical Care Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)
    National Board of Medical Examiners

  • Theodore Liou, MD, is Director of the Adult CF Center at the Ï㽶ÊÓƵ of Utah, Professor of Internal Medicine and Adjunct Associate Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah. He is triple boarded in Internal, Pulmonary and Critical Care Medicine. He has taken care of patients with a highly individualized personal touch and directed the award winning team for CF for more than seventeen years.

    Dr. Liou's research interests include cystic fibrosis, sepsis, ARDS, airway inflammation, pneumonia, airway ecology and antibiotic discovery. He has landmark articles in cystic fibrosis and lung transplantation in journals including JAMA and the New England Journal of Medicine as well as articles with high impact in Lancet, the American Journal of Epidemiology, the American Journal of Respiratory and Critical Care Medicine, CHEST, the Journal of Cystic Fibrosis and others. He has been invited to speak at The Gordon Conference on Enzymes, Co-enzymes and Metabolic pathways, Mayo Clinic, McGill, Case Western, U Penn, Capitol Ï㽶ÊÓƵ Beijing, Children's Hospital LA, USC, Merck, Genentech, the North American CF Conference, the International Conference of the American Thoracic Society, the American Society of Microbiology, the International Society for Heart Lung Transplantation, the Italian CF Research Foundation and the annual European CF society Meetings.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Pediatrics -Adjunct
    Academic Divisions Public Health
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Critical Care Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)
    National Board of Medical Examiners

    Education history

    Fellowship Pulmonary/Critical Care - Ï㽶ÊÓƵ of Utah School of Medicine Fellow
    Residency Internal Medicine - Presbyterian-Ï㽶ÊÓƵ Hospital Resident
    Internship Internal Medicine - Presbyterian-Ï㽶ÊÓƵ Hospital Intern
    Professional Medical Medicine - George Washington Ï㽶ÊÓƵ M.D.
    Undergraduate Biochemistry - Ï㽶ÊÓƵ of California - Berkeley B.A.

    Selected Publications

    Journal Article

    1. Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cyst Fibros. ()
    2. McGarry LJ, Bhaiwala Z, Lopez A, Chandler C, Pelligra CG, Rubin JL, Liou TG (2023). Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data. PLoS One, 18(4), e0283479. ()
    3. Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter MS (2023). Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations. Ann Am Thorac Soc. ()
    4. Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG, Ortega VE, Peters SP, Hoffman EA, Buhr RG, Dolezal BA, Tashkin DP, Liou TG, Bateman LA, Schroeder JD, Martinez FJ, Barr RG, Hansel NN, Comellas AP, Rennard SI, Arjomandi M, Paine Iii R (2022). Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstr Pulm Dis, 9(2), 111-121. ()
    5. Mendoza DL, Pirozzi CS, Crosman ET, Liou TG, Zhang Y, Cleeves JJ, Bannister SC, Anderegg WRL, Robert P 3rd (2020). Impact of low-level fine particulate matter and ozone exposure on absences in K-12 students and economic consequences. Environ Res Lett, 15(11). ()
    6. Liou TG, Kartsonaki C, Keogh RH, Adler FR (2020). Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. Sci Rep, 10(1), 6602. ()
    7. Liou TG, Adler FR, Argel N, Asfour F, Brown PS, Chatfield BA, Daines CL, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Cox DR (2019). Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Med Res Methodol, 19(1), 88. ()
    8. Liou TG (2018). The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease. Chest, 155(3), 605-616. ()
    9. Cirulis MM, Huston JH, Sardar P, Suksaranjit P, Wilson BD, Hatton ND, Liou TG, Ryan JJ (2018). Right-to-left ventricular end diastolic diameter ratio in severe sepsis and septic shock. J Crit Care, 48, 307-310. ()
    10. Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC (2018). Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents Chemother, 62(10). ()
    11. Wozniak CE, Lin Z, Schmidt EW, Hughes KT, Liou TG (2018). Thailandamide, a Fatty Acid Synthesis Antibiotic That Is Coexpressed with a Resistant Target Gene. Antimicrob Agents Chemother, 62(9). ()
    12. Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou TG (2018). Microbial Interactions in the Cystic Fibrosis Airway. J Clin Microbiol, 56(8). ()
    13. Jensen JL, Jones CR, Kartsonaki C, Packer KA, Adler FR, Liou TG (2017). Sleep Phase Delay in Cystic Fibrosis: A Potential New Manifestation of Cystic Fibrosis Transmembrane Regulator Dysfunction. Chest, 152(2), 386-393. ()
    14. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoez CL, Geller DE, VX 08-770-104 Study Group (2012). Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest, 142(3), 718-724. ()
    15. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, Packer K, Clark T, Carveth H, Chen J, Rogers SL, Lane C, Moore J, Sturrock A, Paine R 3rd, Cox DR, Hoidal JR (2012). Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One, 7(8), e42748. ()
    16. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD (2010). Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 122(2), 164-72. ()
    17. Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener JS (2010). Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros, 9(4), 250-6. ()
    18. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD (2010). Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest, 137(2), 376-87. ()
    19. Liou TG, Adler FR, Cox DR, Cahill BC (2007). Lung transplantation and survival in children with cystic fibrosis. N Engl J Med, 357(21), 2143-52. ()
    20. Liou TG, Adler FR, Huang D (2005). Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med, 171(9), 1053-9. ()
    21. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ (2005). Epidemiology of cystic fibrosis-related diabetes. J Pediatr, 146(5), 681-7. ()
    22. Marshall BC, Henshaw C, Evans DA, Bleyl K, Alder S, Liou TG (2002). Influenza vaccination coverage level at a cystic fibrosis center. Pediatrics, 109(5), E80-0. ()
    23. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, Marshall BC (2001). Survival effect of lung transplantation among patients with cystic fibrosis. JAMA, 286(21), 2683-9. ()
    24. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC (2001). Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol, 153(4), 345-52. ()
    25. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, Elstad MR, Campbell EJ, Troyer BE, Whatley RE, Liou TG, Samuelson WM, Carveth HJ, Hinson DM, Morris SE, Davis BL, Day RW (1998). Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med, 157(5 Pt 1), 1372-80. ()
    26. Liou TG, Campbell EJ (1996). Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. J Immunol, 157(6), 2624-31. ()
    27. Liou TG, Campbell EJ (1995). Nonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry, 34(49), 16171-7. ()

    Editorial

    1. Helms MN, Liou TG (2021). Spotlighting "Neutrophil Elastase Triggers the Release of Macrophage Extracellular Traps": A New Catch in Cystic Fibrosis? Am J Respir Cell Mol Biol, 66(1), 5-7. ()

    Letter

    1. Liou TG, Adler FR, Hatton ND (2020). The Uncertain Role of Corticosteroids in the Treatment of COVID-19. [Letter to the editor]. JAMA Intern Med, 181(1), 139-140. ()
    2. Liou TG, Adler FR, Cahill BC (2005). Testing lung function decline to time lung transplantation. [Letter to the editor]. Chest, 128(1), 472-3; author reply 473-4. ()

  • News & Podcasts

    News

  • Clinical Trials